Human pharmacokinetics prediction with an <i>in vitro</i>–<i>in vivo</i> correction factor approach and <i>in vitro</i> drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy<sup>®</sup> for the treatment of HIV-1 infection
Raju Subramanian(Gilead Sciences (United States)), Bill J. Smith(Gilead Sciences (United States)), Jia Hao(Gilead Sciences (United States)), Samantha Wijaya(Gilead Sciences (United States)), Hailing Sun(Gilead Sciences (United States)), Heather Zhang(Gilead Sciences (United States)), Kelly MacLennan Staiger(Gilead Sciences (United States)), Gerry Rhodes(Gilead Sciences (United States)), Jennifer Tang(Gilead Sciences (United States)), Scott E. Lazerwith(University of California, San Francisco), Jianhong Wang(Gilead Sciences (United States)), Joseph M. Custodio(Gilead Sciences (United States)), Judy Mwangi(Gilead Sciences (United States)), Bernard P. Murray(Gilead Sciences (United States)), Kelly Wang(Gilead Sciences (United States))
Cited by 5
Related Papers
Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
|Cell Metabolism|2018|420
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325
Comparison of Information-Dependent Acquisition, SWATH, and MS<sup>All</sup> Techniques in Metabolite Identification Study Employing Ultrahigh-Performance Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry
|Analytical Chemistry|2013|211
Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
|Clinical Pharmacology & Therapeutics|2009|208